ClinicalTrials.gg
CompletedNCT05481736Updated Dec 4, 2024

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

A Phase 2 interventional study of Psilocybin in Anorexia Nervosa, sponsored by COMPASS Pathways. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Enrollment
80th of 142
32 · median 40
Started
2022
with 15 others
Phase 2
20 of 173
5 open now
Registered
126th of 173
by date

Among the 173 studies in Anorexia Nervosa with a site in United States, this one is the 80th largest by enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2022, is one of 20 in phase 2, and was the 126th registered.

Anorexia Nervosa

469 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 173 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 61 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study

Read the detailed description

This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any sex and aged 18 years or above at screening.
  2. Meeting criteria for AN either restrictive or binge-purging type, according to the , based on medical records, clinical assessment, , and documented completion of MINI 7.0.2 and EDE at screening.
  3. Have successfully discontinued all prohibited medications for a period of at least two weeks prior to baseline. For fluoxetine (Prozac), immediate cessation at screening period visit 1a followed by at least four weeks of washout will be required prior to baseline.
  4. Has a history of disordered eating with duration of at least 3 years prior to screening, that is consistent with AN.
  5. BMI ≥15 kg/m2 and ≤20 kg/m2. For participants with a BMI \<16 kg/m2 and >18.5 kg/m2 at screening, approval from the Medical Monitor will be required. Any participant with a BMI >18.5 kg/m2 must meet all of the criteria for AN except that, despite significant weight loss, the individual's weight is within or above the normal range.
  6. Being otherwise medically stable at screening determined by clinical interview, clinical laboratory values, vital signs, , and medical history.
  7. Have at least one documented prior attempt at treatment in the past 3 years.

Exclusion criteria

Exclusion Criteria:

  1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder, or any serious psychiatric comorbidity as assessed by medical history and a structured clinical interview (MINI 7.0.2).
  2. Prior or ongoing paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder based on medical history and clinical judgment.
  3. Borderline personality disorder as demonstrated by medical history, the MINI Plus - BPD and clinical judgment.
  4. Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, at screening or at baseline, or; (2) suicidal behaviours within the past year or; (3) clinical assessment of significant suicidal risk during participant interview.
  5. Current (within last year) alcohol or substance use disorder as informed by the assessed via the MINI 7.0.2, and urine toxicology at screening.
  6. Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
  7. Exposure to psilocybin, or any other psychedelics, such as ayahuasca, mescaline, LSD, or peyote within the past year.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    25 mg COMP360 Psilocybin

    25 mg COMP360 Psilocybin

    Drug: Psilocybin

  • Active comparator
    1 mg COMP360 Psilocybin

    1 mg COMP360 Psilocybin

    Drug: Psilocybin

Interventions

  • COMP360 Psilocybin administered under supportive conditions

    Also known as: COMP360

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Eating Disorder Examination (EDE) global score

    The EDE is a structured clinical interview (investigator rated) used to measure severity of the characteristic psychopathology of eating disorders

    Time frame: Week 4

Secondary outcomes

  1. Safety

    Proportion of patients with adverse events (AEs)

    Time frame: Up to 12 weeks

  2. Change from baseline in Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

    The Y-BOCS self-rated version consists of a 10 item measure with a total score ranging from 0 to 40, with higher scores indicating increased severity of symptoms

    Time frame: Week 4

  3. Change from baseline in weight

    Time frame: Up to 12 weeks

07

Study locations

5 sites
  • Altman Clinical and Translational Research Institute
    San Diego, California 92037, United States
  • Sheppard Pratt Health System
    Baltimore, Maryland 21044, United States
  • Dell Medical School
    Austin, Texas 78712, United States
  • Tallaght University Hospital
    Dublin, Ireland
  • Kings College London, Institute of Psychiatry, Psychology and Neurology
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Nov 2024, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2022
First posted
Aug 1, 2022
StartActual
Oct 12, 2022
Primary completionActual
Nov 18, 2024
CompletionActual
Nov 18, 2024
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05481736
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Aug 1, 2022
Start date
Oct 12, 2022
Primary completion
Nov 18, 2024
Completion
Nov 18, 2024
Last update
Dec 4, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion